TY  - JOUR
AU  - Tošic, Natasa
AU  - Marjanović, Irena
AU  - Lazić, Jelena
PY  - 2023
UR  - https://www.sciencedirect.com/science/article/pii/S0006295223002964
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/2103
AB  - Acute myeloid leukemia (AML) is a very heterogeneous hematological malignancy that accounts for approximately 20% of all pediatric leukemia cases. The outcome of pediatric AML has improved over the last decades, with overall survival rates reaching up to 70%. Still, AML is among the leading types of pediatric cancers by its high mortality rate. Modulation of standard therapy, like chemotherapy intensification, hematopoietic stem cell transplantation and optimized supportive care, could only get this far, but for the significant improvement of the outcome in pediatric AML, development of novel targeted therapy approaches is necessary. In recent years the advances in genomic techniques have greatly expanded our knowledge of the AML biology, revealing molecular landscape and complexity of the disease, which in turn have led to the identification of novel therapeutic targets. This review provides a brief overview of the genetic landscape of pediatric AML, and how it’s used for precise molecular characterization and risk stratification of the patients, and also for the development of effective targeted therapy. Furthermore, this review presents recent advances in molecular targeted therapy and immunotherapy with an emphasis on the therapeutic approaches with significant clinical benefits for pediatric AML.
T2  - Biochemical Pharmacology
T1  - Pediatric acute myeloid leukemia: Insight into genetic landscape and novel targeted approaches
SP  - 115705
VL  - 215
DO  - 10.1016/j.bcp.2023.115705
ER  - 

@article{
author = "Tošic, Natasa and Marjanović, Irena and Lazić, Jelena",
year = "2023",
abstract = "Acute myeloid leukemia (AML) is a very heterogeneous hematological malignancy that accounts for approximately 20% of all pediatric leukemia cases. The outcome of pediatric AML has improved over the last decades, with overall survival rates reaching up to 70%. Still, AML is among the leading types of pediatric cancers by its high mortality rate. Modulation of standard therapy, like chemotherapy intensification, hematopoietic stem cell transplantation and optimized supportive care, could only get this far, but for the significant improvement of the outcome in pediatric AML, development of novel targeted therapy approaches is necessary. In recent years the advances in genomic techniques have greatly expanded our knowledge of the AML biology, revealing molecular landscape and complexity of the disease, which in turn have led to the identification of novel therapeutic targets. This review provides a brief overview of the genetic landscape of pediatric AML, and how it’s used for precise molecular characterization and risk stratification of the patients, and also for the development of effective targeted therapy. Furthermore, this review presents recent advances in molecular targeted therapy and immunotherapy with an emphasis on the therapeutic approaches with significant clinical benefits for pediatric AML.",
journal = "Biochemical Pharmacology",
title = "Pediatric acute myeloid leukemia: Insight into genetic landscape and novel targeted approaches",
pages = "115705",
volume = "215",
doi = "10.1016/j.bcp.2023.115705"
}

Tošic, N., Marjanović, I.,& Lazić, J.. (2023). Pediatric acute myeloid leukemia: Insight into genetic landscape and novel targeted approaches. in Biochemical Pharmacology, 215, 115705.
https://doi.org/10.1016/j.bcp.2023.115705

Tošic N, Marjanović I, Lazić J. Pediatric acute myeloid leukemia: Insight into genetic landscape and novel targeted approaches. in Biochemical Pharmacology. 2023;215:115705.
doi:10.1016/j.bcp.2023.115705 .

Tošic, Natasa, Marjanović, Irena, Lazić, Jelena, "Pediatric acute myeloid leukemia: Insight into genetic landscape and novel targeted approaches" in Biochemical Pharmacology, 215 (2023):115705,
https://doi.org/10.1016/j.bcp.2023.115705 . .

TY  - CONF
AU  - Dokmanović, Lidija
AU  - Janić, Dragana
AU  - Krstovski, Nada
AU  - Lazić, Jelena
AU  - Rodić, Predrag
AU  - Pavlović, Sonja
PY  - 2007
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/274
PB  - Wiley-Liss, Hoboken
C3  - Pediatric Blood & Cancer
T1  - Importance of genotypic analysis of thiopurine S-methyltransferase in children with acute lymphoblastic leukemia
EP  - 424
IS  - 4
SP  - 424
VL  - 49
UR  - https://hdl.handle.net/21.15107/rcub_imagine_274
ER  - 

@conference{
author = "Dokmanović, Lidija and Janić, Dragana and Krstovski, Nada and Lazić, Jelena and Rodić, Predrag and Pavlović, Sonja",
year = "2007",
publisher = "Wiley-Liss, Hoboken",
journal = "Pediatric Blood & Cancer",
title = "Importance of genotypic analysis of thiopurine S-methyltransferase in children with acute lymphoblastic leukemia",
pages = "424-424",
number = "4",
volume = "49",
url = "https://hdl.handle.net/21.15107/rcub_imagine_274"
}

Dokmanović, L., Janić, D., Krstovski, N., Lazić, J., Rodić, P.,& Pavlović, S.. (2007). Importance of genotypic analysis of thiopurine S-methyltransferase in children with acute lymphoblastic leukemia. in Pediatric Blood & Cancer
Wiley-Liss, Hoboken., 49(4), 424-424.
https://hdl.handle.net/21.15107/rcub_imagine_274

Dokmanović L, Janić D, Krstovski N, Lazić J, Rodić P, Pavlović S. Importance of genotypic analysis of thiopurine S-methyltransferase in children with acute lymphoblastic leukemia. in Pediatric Blood & Cancer. 2007;49(4):424-424.
https://hdl.handle.net/21.15107/rcub_imagine_274 .

Dokmanović, Lidija, Janić, Dragana, Krstovski, Nada, Lazić, Jelena, Rodić, Predrag, Pavlović, Sonja, "Importance of genotypic analysis of thiopurine S-methyltransferase in children with acute lymphoblastic leukemia" in Pediatric Blood & Cancer, 49, no. 4 (2007):424-424,
https://hdl.handle.net/21.15107/rcub_imagine_274 .